학술논문
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Document Type
Article
Author
Shohei Koyama; Akbay, Esra A.; Y. Li, Yvonne; Aref, Amir R.; Skoulidis, Ferdinandos; Herter-Sprie, Grit S.; Buczkowski, Kevin A.; Yan Liu; Awad, Mark M.; Denning, Warren L.; Lixia Diao; Jing Wang; Parra-Cuentas, Edwin R.; Wistuba, Ignacio I.; Soucheray, Margaret; Tran Thai; Hajime Asahina; Shunsuke Kitajima; Altabef, Abigail; Cavanaugh, Jillian D.
Source
Subject
*LUNG tumors
*PROTEIN deficiency
*NEUTROPHILS
*CYTOKINES
*T cells
*PHYSIOLOGY
*
*
*
*
*
Language
ISSN
0008-5472
Abstract
STK11/LKB1 is among the most commonly inactivated tumor suppressors in non--small cell lung cancer (NSCLC), especially in tumors harboring KRAS mutations. Many oncogenes promote immune escape, undermining the effectiveness of immunotherapies, but it is unclear whether the inactivation of tumor suppressor genes, such as STK11/LKB1, exerts similar effects. In this study, we investigated the consequences of STK11/LKB1 loss on the immune microenvironment in a mouse model of KRAS-driven NSCLC. Genetic ablation of STK11/LKB1 resulted in accumulation of neutrophilswith T-cell--suppressive effects, along with a corresponding increase in the expression of T-cell exhaustion markers and tumorpromoting cytokines. The number of tumor-infiltrating lymphocytes was also reduced in LKB1-deficient mouse and human tumors. Furthermore, STK11/LKB1--inactivating mutations were associated with reduced expression ofPD-1 ligand PD-L1 inmouse and patient tumors as well as in tumor-derived cell lines.Consistent with these results, PD-1--targeting antibodies were ineffective against Lkb1-deficient tumors. In contrast, treating Lkb1-deficient mice with an IL6-neutralizing antibody or a neutrophil-depleting antibody yielded therapeutic benefits associated with reduced neutrophil accumulation and proinflammatory cytokine expression. Our findings illustrate how tumor suppressor mutations can modulate the immunemilieu of the tumormicroenvironment, and they offer specific implications for addressing STK11/LKB1--mutated tumors withPD-1--targeting antibody therapies. [ABSTRACT FROM AUTHOR]